Kerendia is owned by Bayer Hlthcare.
Kerendia contains Finerenone.
Kerendia has a total of 1 drug patent out of which 0 drug patents have expired.
Kerendia was authorised for market use on 09 July, 2021.
Kerendia is available in tablet;oral dosage forms.
Drug patent challenges can be filed against Kerendia from July, 2025.
The generics of Kerendia are possible to be released after 12 April, 2029.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US8436180||BAYER HLTHCARE||Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof|| |
(6 years from now)
|New Chemical Entity Exclusivity (NCE)||Jul 9, 2026|
|M||Sep 1, 2025|
NCE-1 date: July, 2025
Market Authorisation Date: 09 July, 2021
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic